Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
New blood test detects early-stage pancreatic cancer with high sensitivity in multi-country study
00

New blood test detects early-stage pancreatic cancer with high sensitivity in multi-country study

Sep 16, 2026

A City of Hope-led international study of nearly 1,800 patients reveals that a new investigational blood test, PANXEON, detects stage 1 and 2 pancreatic cancer with 87% sensitivity. The liquid biopsy combines three distinct biomarkers using artificial intelligence to estimate risk. It also identifies precancerous high-grade dysplasia in 64% of cases, offering a non-invasive screening tool for high-risk individuals to improve the disease's low 14% five-year survival rate.

PANXEON blood test development

  • ▪Researchers at City of Hope led the development of PANXEON, an investigational liquid biopsy blood test designed to detect pancreatic cancer at its earliest stages.
  • ▪A large international study evaluating the PANXEON blood test was published in the journal Nature Medicine on September 16, 2026.

Early-stage detection performance

  • ▪The PANXEON blood test demonstrated a false-positive rate of 3% in low-risk groups and 16% in high-risk groups during the multi-country clinical study.
  • ▪In a study of nearly 1,800 patients across the United States, Europe, and Asia, the PANXEON blood test correctly identified stage 1 and 2 pancreatic cancer 87% of the time.
  • ▪The PANXEON blood test detected high-grade dysplasia, an advanced precancerous pancreatic condition, more than 64% of the time in the clinical study.

Multi-biomarker AI methodology

  • ▪PANXEON is the first investigational test to combine three specific biomarkers—circulating microRNAs, exosomal microRNAs, and CA19-9 protein—into a single blood test.
  • ▪The PANXEON test utilizes artificial intelligence to combine measurements of its three target biomarkers into a single score estimating a patient's pancreatic cancer risk.

Pancreatic cancer survival challenge

  • ▪Pancreatic cancer has the lowest survival rate of any cancer, with only 14% of diagnosed patients living five years after their diagnosis.
  • ▪Approximately 90% of pancreatic cancer patients have their tumors detected at advanced stages after the malignancy has already spread.

High-risk screening applications

  • ▪Patients most likely to benefit from PANXEON screening include individuals with inherited genetic risk, a family history of pancreatic cancer, pancreatic cysts, or chronic pancreatitis.
  • ▪The PANXEON blood test is intended to identify high-risk patients who should undergo further evaluation rather than completely replacing imaging or other diagnostic tests.

3 sources

News-medical
Novel blood test could detect pancreatic cancer at its earliest stages
View source article
Nature
Liquid biopsy for early detection of pancreatic ductal adenocarcinoma - Nature Medicine
View source article
Medicalxpress
Blood test shows promise for detecting pancreatic cancer at its earliest stages
View source article

Story comments

Loading comments…

Topics

Cancer TypesCancer Prevention & DiagnosisCancer & OncologyDrug Policy, Pricing & ApprovalDrug Approval and Clinical TrialsBiomarkers & bloodwork testing